Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)
China · Delayed Price · Currency is CNY 10.92
-0.41 (-3.62%)
Feb 13, 2026, 4:00 PM EST
SHE:301301 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,376 | 5,397 | 4,515 | 3,574 | 3,055 | 3,366 |
Other Revenue | 361.61 | 361.61 | 308.58 | 246.72 | 177.08 | 283.45 |
| 4,738 | 5,758 | 4,823 | 3,821 | 3,232 | 3,649 | |
Revenue Growth (YoY) | -16.85% | 19.38% | 26.24% | 18.21% | -11.44% | 16.10% |
Cost of Revenue | 3,129 | 3,680 | 3,343 | 2,890 | 2,637 | 3,007 |
Gross Profit | 1,609 | 2,078 | 1,480 | 930.89 | 595.07 | 641.97 |
Selling, General & Admin | 227.3 | 190.87 | 165.7 | 155.54 | 130.22 | 122.59 |
Research & Development | 117.3 | 77.73 | 55.26 | 35.38 | 32.95 | 25.05 |
Other Operating Expenses | 57.58 | 79.51 | 66.52 | 54.94 | 36.7 | 36.14 |
Operating Expenses | 405.94 | 341.43 | 293.98 | 260.12 | 198.27 | 184.53 |
Operating Income | 1,203 | 1,737 | 1,186 | 670.77 | 396.8 | 457.44 |
Interest Expense | -57.46 | -61.91 | -87.78 | -142.34 | -176.88 | -173.66 |
Interest & Investment Income | 5.71 | 7.38 | 16.18 | 5.21 | 9.2 | 3.11 |
Currency Exchange Gain (Loss) | 6.69 | 6.69 | 12.18 | 14.71 | -5.37 | -8.35 |
Other Non Operating Income (Expenses) | 9.09 | -5.83 | -3.74 | -0.64 | -0.95 | -1.48 |
EBT Excluding Unusual Items | 1,167 | 1,683 | 1,123 | 547.7 | 222.8 | 277.07 |
Gain (Loss) on Sale of Investments | -4.9 | -9.16 | -14.73 | -8.96 | 0.55 | 0.42 |
Gain (Loss) on Sale of Assets | 0.35 | - | 1.34 | - | 0.26 | - |
Asset Writedown | -14.68 | - | - | - | -5.79 | -1.41 |
Other Unusual Items | 1.22 | 1.22 | 7.97 | -51.11 | -83.74 | - |
Pretax Income | 1,149 | 1,675 | 1,118 | 487.63 | 134.08 | 276.07 |
Income Tax Expense | 213.65 | 274.74 | 177.15 | 76.11 | 22.73 | 47.07 |
Earnings From Continuing Operations | 935.3 | 1,400 | 940.56 | 411.52 | 111.35 | 229 |
Minority Interest in Earnings | 0.5 | -0.03 | -0 | 0 | -0 | -0 |
Net Income | 935.8 | 1,400 | 940.56 | 411.52 | 111.35 | 229 |
Net Income to Common | 935.8 | 1,400 | 940.56 | 411.52 | 111.35 | 229 |
Net Income Growth | -32.01% | 48.88% | 128.56% | 269.58% | -51.38% | 150.58% |
Shares Outstanding (Basic) | 2,240 | 2,223 | 2,239 | 1,960 | 1,856 | 2,000 |
Shares Outstanding (Diluted) | 2,240 | 2,223 | 2,239 | 1,960 | 1,856 | 2,000 |
Shares Change (YoY) | -1.11% | -0.75% | 14.28% | 5.59% | -7.21% | - |
EPS (Basic) | 0.42 | 0.63 | 0.42 | 0.21 | 0.06 | 0.11 |
EPS (Diluted) | 0.42 | 0.63 | 0.42 | 0.21 | 0.06 | 0.11 |
EPS Growth | -31.25% | 50.00% | 100.00% | 250.00% | -45.45% | - |
Free Cash Flow | 1,459 | 1,748 | 947.26 | 644.44 | 750.94 | 560.59 |
Free Cash Flow Per Share | 0.65 | 0.79 | 0.42 | 0.33 | 0.41 | 0.28 |
Dividend Per Share | 0.270 | 0.270 | 0.225 | 0.093 | - | - |
Dividend Growth | 19.84% | 19.84% | 141.94% | - | - | - |
Gross Margin | 33.96% | 36.09% | 30.69% | 24.37% | 18.41% | 17.59% |
Operating Margin | 25.39% | 30.16% | 24.59% | 17.56% | 12.28% | 12.53% |
Profit Margin | 19.75% | 24.32% | 19.50% | 10.77% | 3.45% | 6.28% |
Free Cash Flow Margin | 30.79% | 30.36% | 19.64% | 16.87% | 23.23% | 15.36% |
EBITDA | 1,743 | 2,278 | 1,730 | 1,217 | 919.79 | 948.73 |
EBITDA Margin | 36.79% | 39.57% | 35.87% | 31.85% | 28.46% | 26.00% |
D&A For EBITDA | 540.35 | 541.74 | 543.6 | 546.07 | 522.99 | 491.29 |
EBIT | 1,203 | 1,737 | 1,186 | 670.77 | 396.8 | 457.44 |
EBIT Margin | 25.39% | 30.16% | 24.59% | 17.56% | 12.28% | 12.53% |
Effective Tax Rate | 18.59% | 16.40% | 15.85% | 15.61% | 16.96% | 17.05% |
Revenue as Reported | 4,738 | 5,758 | 4,823 | 3,821 | 3,232 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.